Accumulated research has revealed the decreased expression of LPAR1 and its migration-inhibiting effects in tumors including prostate cancer, gastric cancer and pancreatic cancer, which is consistent with our results [7,12,13]. This evidence concerns the gene LPAR1 and prostate carcinoma.